Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, January 29th. Analysts expect the company to ...

The Delaware Supreme Court affirmed Friday a trial court’s decision in favor of Teva Pharmaceutical Industries Ltd.'s US unit ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price target raised by UBS Group from $28.00 to $30.00 in a research note published on Thursday,Benzinga reports. UBS Group currently ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva ...

UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...

Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on TEVA stock, giving a Buy rating on January 21.Invest ...

The Delaware Supreme Court appeared skeptical Wednesday of arguments that a trial judge misinterpreted contract language ...

Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.44 which represents a decrease of $-0.50 or -2.39% from the prior close of $20.94. The stock opened at $20.95 and ...

1 Day TEVA 1.11% DJIA 0.78% S&P 500 1.00% Health Care/Life Sciences 66.70% ...